Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Eng C. et al, (2019), Lancet Oncol, 20, 849 - 861

Association analyses identify 31 new risk loci for colorectal cancer susceptibility.

Law PJ. et al, (2019), Nat Commun, 10

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.

Gray V. et al, (2019), J Natl Cancer Inst

SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer.

Robles-Zurita J. et al, (2018), Br J Cancer, 119, 1332 - 1338

Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E. et al, (2018), Lancet Gastroenterol Hepatol, 3, 635 - 643

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.

Iveson TJ. et al, (2018), Lancet Oncol, 19, 562 - 578

The value of additional bevacizumab in patients with high-risk stroma-high colon cancer. A study within the QUASAR2 trial, an open-label randomized phase 3 trial.

Huijbers A. et al, (2018), J Surg Oncol, 117, 1043 - 1048

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.

Grothey A. et al, (2018), N Engl J Med, 378, 1177 - 1188

Prognostic markers for colorectal cancer: estimating ploidy and stroma.

Danielsen HE. et al, (2018), Ann Oncol, 29, 616 - 623

Genome-wide association study and meta-analysis in Northern European populations replicate multiple colorectal cancer risk loci.

Tanskanen T. et al, (2018), Int J Cancer, 142, 540 - 546

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis.

May-Wilson S. et al, (2017), Eur J Cancer, 84, 228 - 238

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer.

Rodriguez-Broadbent H. et al, (2017), Int J Cancer, 140, 2701 - 2708

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

Kerr RS. et al, (2016), Lancet Oncol, 17, 1543 - 1557

Is sidedness prognostically important across all stages of colorectal cancer?

Kerr DJ. et al, (2016), Lancet Oncol, 17, 1480 - 1482

Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.

Domingo E. et al, (2016), Lancet Gastroenterol Hepatol, 1, 207 - 216

Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.

Jarvis D. et al, (2016), Br J Cancer, 115, 266 - 272

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.

Orlando G. et al, (2016), Hum Mol Genet, 25, 2349 - 2359

Screening for Lynch syndrome and referral to clinical genetics by selective mismatch repair protein immunohistochemistry testing: an audit and cost analysis.

Colling R. et al, (2015), J Clin Pathol, 68, 1036 - 1039

Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Al-Tassan NA. et al, (2015), Sci Rep, 5

A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer.

Al-Tassan NA. et al, (2015), Sci Rep, 5

Load More

1
2
3
4
5
6
7
...
»